Signature Dx to Launch Two Colorectal Tests on Affy Platform
June 29, 2010
Signature Dx to Launch Two Colorectal Tests on Affy Platform
Potsdam-based Signature Dx plans to launch by the fourth quarter of this year two array-based in vitro diagnostics for colorectal cancer. The company will first launch the tests in Europe and intends to seek US regulatory approval at an unspecified time in the future.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Almac Dx Plans to Debut Array-based Colorectal Cancer-Recurrence Test Next Year
November 15, 2011 / BioArray News - Affymetrix's Shares Jump 30 Percent in June to Lead GWDN Index
July 1, 2011 / GenomeWeb Daily News - Despite Years of Development, Affymetrix's Dx Partners Slow to Bring Tests to Market
March 15, 2011 / BioArray News - In 2010, Array Makers Saw CGH Become the Standard in Cytogenetics, Prepared for Next Wave of GWAS
January 4, 2011 / BioArray News - Signature Dx to Use Affymetrix Chips for Cancer Test Development
June 28, 2010 / GenomeWeb Daily News